Overall rank by patents
#45,473
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2016–2018. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G07F (COIN-FREED OR LIKE APPARATUS).
The verdict
Cellomat holds 5 US patents across 3 technology areas, rank #45,473 of 50,000 tracked assignees.
Cellomat Israel Ltd. has been granted 5 US utility patents between 2016 and 2018, placing Cellomat Israel Ltd. at rank #45,473 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 31.4 claims per patent with primary concentration in G07F (COIN-FREED OR LIKE APPARATUS). As a Foreign Corporation, Cellomat Israel Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Cellomat sits between Cedes Safety & Automation Ag (5 patents, rank #45,469) and Censhare Gmbh (5 patents, rank #45,477) - the closest US assignees by grant volume. The composite Innovation Score of 27.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 5 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Cellomat Israel Ltd.'s 31.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Cellomat Israel Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
CEDES SAFETY & AUTOMATION AG
5 patents
CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
5 patents
CELLACT PHARMA GMBH
5 patents
CELLBLOCK FCS, LLC
5 patents
CELONOVA STENT, INC.
5 patents
CELSIA TECHNOLOGIES TAIWAN, INC.
5 patents
CENDRES+METAUX SA
5 patents
CENSHARE GMBH
5 patents
CELLOMAT ISRAEL LTD.
5 patents
What this shows Cellomat holds 5 patents at rank #45,473, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #45,473 in granted patent volume.
Other assignees with the most granted patents in Cellomat's primary technology class.
Cellomat's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 77% higher than 23% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 4 | 80.0% |
| 2018 | 1 | 20.0% |
Top 3 of 3 technology areas
Overall rank by patents
#45,473
Across all tracked assignees
27.3 out of 100
How to use this portfolio
Cellomat's 5 grants land it in the top 77% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.